Skip to main content
Erschienen in: Journal of Nanoparticle Research 11/2017

01.11.2017 | Research Paper

Small gold nanoparticles presenting linear and looped Cilengitide analogues as radiosensitizers of cells expressing ανβ3 integrin

verfasst von: Adam R. Travis, Virginia A. Liau, Amanda C. Agrawal, David E. Cliffel

Erschienen in: Journal of Nanoparticle Research | Ausgabe 11/2017

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config
loading …

Abstract

This work uses linear and looped RGDfV sequences attached to the surface of small (1.8 nm in diameter) gold nanoparticles (AuNPs) to enhance the radiosensitizating effects of Cilengitide, a cyclic RGDf (NMe)V pentapeptide that targets αvβ3 integrin which is overexpressed in certain cancers. Following synthesis and purification, the AuNPs were evaluated in vitro against HUVEC, H460, and MCF7 cells in clonogenic assays using a 137Cs irradiator. Untargeted AuNPs induced no significant dose enhancement factors (DEFs) in any of the cell types when compared to radiation treatment alone, whereas all evaluated AuNPs functionalized with targeting peptides performed at least as well as controls (irradiation after Cilengitide treatment). The observed DEFs also suggest that cyclizing the linear peptides into more spatially constrained, looped structures may facilitate target binding. These greater dose enhancements merit future in vivo studies of drug-AuNP conjugates to assess the ability of the nanostructures to provide an improved therapeutic benefit over treatment with drug candidates and radiation alone.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 390 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Maschinenbau + Werkstoffe




 

Jetzt Wissensvorsprung sichern!

Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Chen K, Chen X (2011) Integrin targeted delivery of chemotherapeutics. Theranostics 1:189–200CrossRef Chen K, Chen X (2011) Integrin targeted delivery of chemotherapeutics. Theranostics 1:189–200CrossRef
Zurück zum Zitat Ellis LM (2002) Tumor angiogenesis. Horizons in Cancer Therapeutics: From Bench to Bedside 3:4–22 Ellis LM (2002) Tumor angiogenesis. Horizons in Cancer Therapeutics: From Bench to Bedside 3:4–22
Zurück zum Zitat Fowler J, Adams G, Denekamp J (1976) Radiosensitizers of hypoxic cells in solid tumours. Cancer Treat Rev 3:227–256CrossRef Fowler J, Adams G, Denekamp J (1976) Radiosensitizers of hypoxic cells in solid tumours. Cancer Treat Rev 3:227–256CrossRef
Zurück zum Zitat Healy JM, Murayama O, Maeda T et al (1995) Peptide ligands for integrin alpha v beta 3 selected from random phage display libraries. Biochemistry 34:3948–3955CrossRef Healy JM, Murayama O, Maeda T et al (1995) Peptide ligands for integrin alpha v beta 3 selected from random phage display libraries. Biochemistry 34:3948–3955CrossRef
Zurück zum Zitat Liu S (2009) Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjug Chem 20:2199–2213CrossRef Liu S (2009) Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjug Chem 20:2199–2213CrossRef
Zurück zum Zitat Manegold C, Vansteenkiste J, Cardenal F et al (2013) Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer. Investig New Drugs 31:175–182. https://doi.org/10.1007/s10637-012-9842-6 CrossRef Manegold C, Vansteenkiste J, Cardenal F et al (2013) Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer. Investig New Drugs 31:175–182. https://​doi.​org/​10.​1007/​s10637-012-9842-6 CrossRef
Zurück zum Zitat Mas-Moruno C, Rechenmacher F, Kessler H (2010) Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anti Cancer Agents Med Chem 10:753–768 Mas-Moruno C, Rechenmacher F, Kessler H (2010) Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anti Cancer Agents Med Chem 10:753–768
Zurück zum Zitat Samant RS, Shevde LA (2011) Recent advances in anti-angiogenic therapy of cancer abstract: VEGF matrix degradation MMPs sunitinib sorafenib rapamycin bFGF TGF- α bevacizumab cetuximab panitumumab erlotinib (TKI). Oncotarget 2:122–134CrossRef Samant RS, Shevde LA (2011) Recent advances in anti-angiogenic therapy of cancer abstract: VEGF matrix degradation MMPs sunitinib sorafenib rapamycin bFGF TGF- α bevacizumab cetuximab panitumumab erlotinib (TKI). Oncotarget 2:122–134CrossRef
Zurück zum Zitat Schaaf TG, Knight G, Shafigullin MN, Borkman RF, Wetten RL (1998) Isolation and selected properties of a 10.4 kDa gold: glutathione cluster compound. J Phys Chem B 102:10643–10646 Schaaf TG, Knight G, Shafigullin MN, Borkman RF, Wetten RL (1998) Isolation and selected properties of a 10.4 kDa gold: glutathione cluster compound. J Phys Chem B 102:10643–10646
Zurück zum Zitat Templeton AC, Chen S, Gross SM et al (1999) Water-soluble, isolable gold clusters protected by tiopronin and coenzyme A monolayers. Langmuir 15:66–76 Templeton AC, Chen S, Gross SM et al (1999) Water-soluble, isolable gold clusters protected by tiopronin and coenzyme A monolayers. Langmuir 15:66–76
Zurück zum Zitat Vansteenkiste J, Barlesi F, Waller CF et al (2015) Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO). Ann Oncol:1734–1740. https://doi.org/10.1093/annonc/mdv219 Vansteenkiste J, Barlesi F, Waller CF et al (2015) Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO). Ann Oncol:1734–1740. https://​doi.​org/​10.​1093/​annonc/​mdv219
Metadaten
Titel
Small gold nanoparticles presenting linear and looped Cilengitide analogues as radiosensitizers of cells expressing ανβ3 integrin
verfasst von
Adam R. Travis
Virginia A. Liau
Amanda C. Agrawal
David E. Cliffel
Publikationsdatum
01.11.2017
Verlag
Springer Netherlands
Erschienen in
Journal of Nanoparticle Research / Ausgabe 11/2017
Print ISSN: 1388-0764
Elektronische ISSN: 1572-896X
DOI
https://doi.org/10.1007/s11051-017-4041-1

Weitere Artikel der Ausgabe 11/2017

Journal of Nanoparticle Research 11/2017 Zur Ausgabe

    Marktübersichten

    Die im Laufe eines Jahres in der „adhäsion“ veröffentlichten Marktübersichten helfen Anwendern verschiedenster Branchen, sich einen gezielten Überblick über Lieferantenangebote zu verschaffen.